A Phase 1A/B Study to Evaluate the Safety and Tolerability of EBC-129 As a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumours

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs EBC-129 (Primary) ; Pembrolizumab (Primary)
Indications Colorectal cancer; Gastric cancer; Lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

03 Jan 2025 The protocol has been amended.
12 Oct 2023 Planned End Date changed from 4 May 2025 to 11 Jun 2026.
12 Oct 2023 Planned primary completion date changed from 19 Apr 2025 to 11 Jun 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com